| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -38.00 | -0.32% | 11,712.00 | 11,726.00 | 11,730.00 | 11,858.00 | 11,710.00 | 11,858.00 | 947,374 | 16:35:01 |
| Industry Sector | Turnover (m) | Profit (m) | EPS - Basic | PE Ratio | Market Cap (m) |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | - | - | 212.2 | 55.4 | 181,512.58 |
AstraZeneca PLC Total Voting Rights
01/02/2023 3:00pm
UK Regulatory (RNS & others)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Dec 2022 to Jun 2023
TIDMAZN
RNS Number : 6061O
AstraZeneca PLC
01 February 2023
1 February 2023 15:00 GMT
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 January 2023 the issued share capital of AstraZeneca PLC with voting rights is 1,549,818,422 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,549,818,422.
The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TVRFLFFLFVILIIV
(END) Dow Jones Newswires
February 01, 2023 10:00 ET (15:00 GMT)
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |